These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25624711)

  • 1. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
    Wang H; Lu Y; Wang M; Wu Y; Wang X; Li Y
    J Mol Med (Berl); 2021 Feb; 99(2):193-212. PubMed ID: 33392633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of E3 ubiquitin ligases in lung cancer.
    Snoek BC; de Wilt LH; Jansen G; Peters GJ
    World J Clin Oncol; 2013 Aug; 4(3):58-69. PubMed ID: 23936758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment.
    Song Q; Feng S; Peng W; Li A; Ma T; Yu B; Liu HM
    Pharmacol Res; 2021 Aug; 170():105493. PubMed ID: 33600940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ubiquitin ligases as cancer targets and biomarkers.
    Sun Y
    Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of the HECT E3 ubiquitin ligases in gastric cancer.
    Sun A; Tian X; Chen Y; Yang W; Lin Q
    Pathol Oncol Res; 2023; 29():1610931. PubMed ID: 36825281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
    Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA; Smith PG; Rolfe M
    Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of approaches for screening for ubiquitin ligase inhibitors.
    Sun Y
    Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ubiquitin ligases in cancer and implications for therapies.
    Wang D; Ma L; Wang B; Liu J; Wei W
    Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
    Daks AA; Melino D; Barlev NA
    Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted modulation of E3 ligases using engineered ubiquitin variants.
    LeBlanc N; Mallette E; Zhang W
    FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
    Landré V; Rotblat B; Melino S; Bernassola F; Melino G
    Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.